Matthias M. Engelen

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

Timothy Devos, Quentin Van Thillo, Veerle Compernolle et al. · European Respiratory Journal · 2021 · 48 citations · Full text

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial

Laurens Liesenborghs, Isabel Spriet, Dirk Jochmans et al. · EBioMedicine · 2021 · 33 citations · Full text

Preclinical Studies, Covid-19 Pandemic, Antiviral Therapy +6

Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19

Caroline P. Martens, Pierre Van Mol, Joost Wauters et al. · EBioMedicine · 2022 · 31 citations · Full text

Kallikrein-kinin System, Respiratory Diseases, Immunology +6

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

Thomas Vanassche, Matthias M. Engelen, Quentin Van Thillo et al. · Trials · 2020 · 18 citations · Full text